These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29448040)

  • 1. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
    Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
    Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
    Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA
    Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
    Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
    Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
    Tavares GSV; Mendonça DVC; Miyazaki CK; Lage DP; Soyer TG; Carvalho LM; Ottoni FM; Dias DS; Ribeiro PAF; Antinarelli LMR; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Parasitol Int; 2019 Feb; 68(1):63-72. PubMed ID: 30339837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
    Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
    Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
    Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
    Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
    Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clioquinol-containing Pluronic
    Tavares GSV; Mendonça DVC; Pereira IAG; Oliveira-da-Silva JA; Ramos FF; Lage DP; Machado AS; Carvalho LM; Reis TAR; Perin L; Carvalho AMRS; Ottoni FM; Ludolf F; Freitas CS; Bandeira RS; Silva AM; Chávez-Fumagalli MA; Duarte MC; Menezes-Souza D; Alves RJ; Roatt BM; Coelho EAF
    Parasite; 2020; 27():29. PubMed ID: 32351209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
    Asad M; Bhattacharya P; Banerjee A; Ali N
    BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.
    Ribeiro Antinarelli LM; Glanzmann N; Mendonça DVC; Lage DP; Oliveira-da-Silva JA; Tavares GSV; Carvalho AMRS; Freitas CS; Martins VT; Duarte MC; Menezes-Souza D; da Silva AD; Coelho EAF; Soares Coimbra E
    Parasitol Res; 2022 Jul; 121(7):2129-2140. PubMed ID: 35614147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis.
    Soyer TG; Bandeira Câmara RS; Pereira IAG; Ramos FF; de Jesus MM; Ludolf F; de Paula Costa G; Lage DP; de Freitas CS; Vale DL; Pimenta BL; Martins VT; Galdino AS; Chávez-Fumagalli MA; Roatt BM; de Sousa Vieira Tavares G; Coelho EAF
    Parasite Immunol; 2024 May; 46(5):e13037. PubMed ID: 38720446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
    Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
    Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis.
    Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Martins VT; Costa LE; Lage PS; Ribeiro TG; Castilho RO; Fernandes AP; Régis WC; Soto M; Tavares CA; Coelho EA
    Exp Parasitol; 2012 Oct; 132(2):228-36. PubMed ID: 22824583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case.
    Gomes MAF; Medeiros LLC; Lobo FPD; Wanderley NRS; Matos APR; Jácome TDN; Monteiro MGL; Luz KG
    Rev Soc Bras Med Trop; 2018; 51(3):393-396. PubMed ID: 29972577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.